Cargando…

Subclass analysis of donor HLA‐specific IgG in antibody‐incompatible renal transplantation reveals a significant association of IgG(4) with rejection and graft failure

Donor HLA‐specific antibodies (DSAs) can cause rejection and graft loss after renal transplantation, but their levels measured by the current assays are not fully predictive of outcomes. We investigated whether IgG subclasses of DSA were associated with early rejection and graft failure. DSA levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Khovanova, Natasha, Daga, Sunil, Shaikhina, Torgyn, Krishnan, Nithya, Jones, James, Zehnder, Daniel, Mitchell, Daniel, Higgins, Robert, Briggs, David, Lowe, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975692/
https://www.ncbi.nlm.nih.gov/pubmed/26264744
http://dx.doi.org/10.1111/tri.12648
Descripción
Sumario:Donor HLA‐specific antibodies (DSAs) can cause rejection and graft loss after renal transplantation, but their levels measured by the current assays are not fully predictive of outcomes. We investigated whether IgG subclasses of DSA were associated with early rejection and graft failure. DSA levels were determined pretreatment, at the day of peak pan‐IgG level and at 30 days post‐transplantation in eighty HLA antibody‐incompatible kidney transplant recipients using a modified microbead assay. Pretreatment IgG(4) levels were predictive of acute antibody‐mediated rejection (P = 0.003) in the first 30 days post‐transplant. Pre‐treatment presence of IgG(4) DSA (P = 0.008) and day 30 IgG(3) DSA (P = 0.03) was associated with poor graft survival. Multivariate regression analysis showed that in addition to pan‐IgG levels, total IgG(4) levels were an independent risk factor for early rejection when measured pretreatment, and the presence of pretreatment IgG(4) DSA was also an independent risk factor for graft failure. Pretreatment IgG(4) DSA levels correlated independently with higher risk of early rejection episodes and medium‐term death‐censored graft survival. Thus, pretreatment IgG(4) DSA may be used as a biomarker to predict and risk stratify cases with higher levels of pan‐IgG DSA in HLA antibody‐incompatible transplantation. Further investigations are needed to confirm our results.